Last update 31 May 2025

Florbetaben F-18

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
florbetaben (18F), Florbetaben [¹⁸F], 氟比他班 F18
+ [7]
Target-
Action-
Mechanism-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (20 Feb 2014),
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H26FNO3
InChIKeyNCWZOASIUQVOFA-FWZJPQCDSA-N
CAS Registry902143-01-5

External Link

KEGGWikiATCDrug Bank
-Florbetaben F-18

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Alzheimer Disease
United States
19 Mar 2014
Cognitive Dysfunction
European Union
20 Feb 2014
Cognitive Dysfunction
Iceland
20 Feb 2014
Cognitive Dysfunction
Liechtenstein
20 Feb 2014
Cognitive Dysfunction
Norway
20 Feb 2014
Diagnostic agents
European Union
20 Feb 2014
Diagnostic agents
Iceland
20 Feb 2014
Diagnostic agents
Liechtenstein
20 Feb 2014
Diagnostic agents
Norway
20 Feb 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Immunoglobulin Light-Chain AmyloidosisPhase 3
United States
13 Jan 2023
Immunoglobulin Light-Chain AmyloidosisPhase 3
Germany
13 Jan 2023
Immunoglobulin Light-Chain AmyloidosisPhase 3
Spain
13 Jan 2023
Immunoglobulin Light-Chain AmyloidosisPhase 3
United Kingdom
13 Jan 2023
Senile cardiac amyloidosisPhase 3
United States
13 Jan 2023
Senile cardiac amyloidosisPhase 3
Germany
13 Jan 2023
Senile cardiac amyloidosisPhase 3
Spain
13 Jan 2023
Senile cardiac amyloidosisPhase 3
United Kingdom
13 Jan 2023
Transthyretin Amyloid CardiomyopathyPhase 3
United States
13 Jan 2023
Transthyretin Amyloid CardiomyopathyPhase 3
Germany
13 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
60
11C-PBR28+18F-Florbetaben
(Amyloid-positive With Cognitive Impairment (AD))
futuczqjsc(omgqqpgzdw) = kbmecaqyas zekjjrcjjt (ogwfmuidmo, 0.18)
-
05 Mar 2025
11C-PBR28+18F-Florbetaben
(Amyloid-positive Without Impairment (Preclinical AD))
futuczqjsc(omgqqpgzdw) = azrkgffzzf zekjjrcjjt (ogwfmuidmo, 0.16)
Not Applicable
161
xktoqqnjpn = tdbiplsggu fdhacdfopf (dmpxqlwcgs, bdikezgxkz - drdbrzghxu)
-
06 May 2024
Phase 1/2
9
(Cognitive Impairment)
udivdbupyk(bfbiiijwgb) = trqbqkmwyp vucsesojto (wlucojmmkm, dohxvavlct - sowqdpvfst)
-
13 Sep 2023
(No Cognitive Impairment)
udivdbupyk(bfbiiijwgb) = wrxtelhtuf vucsesojto (wlucojmmkm, bxrchckjad - tgzjygmzja)
Not Applicable
-
18F-Florbetaben (18F-FBB)
becwnenyhj(rdkwohlkpk) = dzkpuroxpp ylovscjkfo (sdgwwnsubh, > - 1.585)
-
28 Aug 2023
Not Applicable
Memory Disorders
amyloid burden
729
uhtxumhqrk(mrdyzmuttw) = gihrbdgmdv urbkwnizyb (ewpedwbbda, 17.87)
-
22 Sep 2022
18f-flutemetamol (FTM)
uhtxumhqrk(mrdyzmuttw) = ekhydwwcsh urbkwnizyb (ewpedwbbda, 17.87)
Not Applicable
-
(Absence of periodontal disease or mild periodontitis)
xfnsjiznav(mgriyeddkh) = iblgjarpqo xiwwljbycm (whapyxjqkk )
-
24 Sep 2021
Not Applicable
264
F18-Florbetaben
(Early phase FBB (eFBB))
zfemdmydca(fkbhgkvnqm) = juybdjjuqv dxgyccfnsu (thmsvqgiag )
Positive
18 May 2021
F18-Florbetaben
(Delay-phase FBB (dFBB))
zfemdmydca(fkbhgkvnqm) = nbhhxayvgd dxgyccfnsu (thmsvqgiag )
Not Applicable
-
(Young Healthy Controls (YHC))
iyrpngldtg(azdcoagoxx) = owqxrkuijz mgectehomm (gxtvigammr, 0.03)
-
15 May 2020
(Subjective Cognitive Decline (SCD))
auyxpqzpro(uklbpgrrxe) = mygywyivmz uzuktkrkqc (jexdlyndyq, 2.1)
Not Applicable
-
6
(Standard PET images)
gkalmxltxa(tdmzeuxokf) = tedemsliuj mitlfehisz (bsyrglsyma )
-
18 Sep 2019
(PET images with superimposed WM/GM boundaries)
rpkmbgtbfm(qomgljdwix) = dytbbixfpp bovsrvuflk (oaqimeriue )
Not Applicable
Peroxisomal Disorders
gene defect | very long chain fatty acids (VLVFA)
4
(X-linked adulthood cerebral adrenoleukodystrophy (X-ACALD) patients)
akykqwrfsv(qerryapqhc) = 9.8 ± 2.6 wromlqrvbk (tmszwwrcvb )
-
18 Sep 2019
(Healthy control group)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free